Company / Depreciation & Amortization
Bristol Myers Squibb Depreciation & Amortization History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Depreciation & Amortization
$4.0B
FY2025
5-year range
$1.7B / $10.7B
FY2021-FY2025
Trend
-58.2%
vs FY2024
Sector context
#4 of 168
Health Care
What the data says
Among 168 Health Care companies, Bristol Myers Squibb is in the bottom 2% for depreciation & amortization. Depreciation & Amortization has fluctuated over the past 10 years, ranging from $382M in FY2018 to $10.7B in FY2023.
Based on SEC 10-K filings.
$4.0B in FY2025 with a 5-year CAGR of -17.3%. Top quartile in the Health Care sector.
Improved from $10.7B to $4.0B over the past 2 years.
Health Care sector context is included.
Depreciation & Amortization over time
Growth rates
- 3-Year CAGR
- -27.2%
- 5-Year CAGR
- -17.3%
- 10-Year CAGR
- -
Sector benchmark
+1783.8% above sector average
Key checks
Key Insights
- 5-year CAGR of -17.3%, indicating a declining trend.
- In FY2025, depreciation & amortization decreased 58.2% year-over-year.
- Ranks #4 out of 168 companies in the Health Care sector.
- Peak depreciation & amortization was recorded in FY2023.
Company context
Key Data Points
- High Piotroski F-Score: 8/9 (strong financial health signals)
- Altman Z-Score 0.85 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
- Strong return on equity: 32.6%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Depreciation & AmortizationValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $4.0B | -58.2% |
| FY2024 | $9.6B | -10.2% |
| FY2023 | $10.7B | +2.9% |
| FY2022 | $10.4B | +494.5% |
| FY2021 | $1.7B | -83.2% |
| FY2020 | $10.4B | +1215.6% |
| FY2019 | $789.0M | +106.5% |
| FY2018 | $382.0M | -51.6% |
| FY2017 | $789.0M | +69.0% |
| FY2016 | $467.0M | -38.8% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026